반려동물 재생의료 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 동물별, 용도별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Companion Animal Regenerative Medicine Market Summary

The global companion animal regenerative medicine market size was estimated at USD 1.14 billion in 2025 and is projected to reach USD 2.28 billion by 2033, growing at a CAGR of 9.38% from 2026 to 2033. The market is growing significantly due to increasing technological breakthroughs in stem cell engineering and translational research, rising commercial adoption and veterinary demand for advanced therapies and growing awareness and demand for regenerative medicine in companion animals.

Technological progress in stem cell biology and regenerative engineering is significantly advancing therapeutic capabilities in companion animal healthcare. Some of the innovations such as in cell culture systems, differentiation control, and functional tissue generation are enabling the development of highly specialized regenerative treatments. Besides this, breakthroughs allowing stem cells to transform into functional cardiac and other tissue-specific cells are expanding applications in disease modeling, drug testing, and precision therapies. For instance, in November 2025, researchers at Osaka Metropolitan University developed a new culture medium enabling canine iPS stem cells to reliably differentiate into functional, contracting heart muscle cells, advancing regenerative medicine research and veterinary drug discovery applications. These advancements improve treatment reliability, reproducibility, and scalability, strengthening clinical translation from research to veterinary practice. Moreover, translational research leveraging similarities between human and animal diseases is accelerating innovation pipelines, enhancing therapeutic effectiveness, and supporting long-term growth of regenerative medicine applications across multiple companion animal disease areas.

Moreover, the companion animal regenerative medicine industry is being propelled by increasing commercial deployment of innovative therapeutic platforms across veterinary practices. The growing numbers of certified treatment centers and expanding service networks are improving accessibility to advanced regenerative solutions. Besides this, the rising volume of administered therapies across multiple animal species reflects accelerating clinical adoption and operational scalability. In addition, veterinary institutions are integrating regenerative procedures into treatment protocols for oncology, orthopedic injuries, and chronic degenerative conditions in large number. According to a report of January 2025, a University of Missouri clinical trial used CAR T-cell therapy to treat lymphoma in a dog, reducing tumor swelling and showing promising potential for advancing cancer treatment in animals. This trend is further supported by industry initiatives focused on improving treatment affordability, enhancing clinical outcomes documentation, and expanding practitioner training programs.

Furthermore, rising awareness among veterinarians and pet owners regarding regenerative therapies is increasing significantly, driving market expansion. The growing recognition of stem cell based treatments as viable alternatives for conditions where conventional therapies are limited is encouraging adoption. Similarly, rising education efforts, clinical case reporting, and positive treatment outcomes are strengthening confidence in regenerative approaches. Besides this, increasing demand for advanced, minimally invasive treatment options that improve recovery, functionality, and quality of life in companion animals is accelerating its adoption. Moreover, expanding availability of specialized veterinary centers offering regenerative procedures and the growing willingness of pet owners to invest in advanced care are reinforcing sustained market demand and supporting broader commercialization of regenerative medicine solutions.

Global Companion Animal Regenerative Medicine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the companion animal regenerative medicine market report based on product, animal, application, end use, and region.

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Stem Cells
• Platelet-Rich Plasma (PRP)
• Other Products
• Animal Outlook (Revenue, USD Million, 2021 - 2033)
• Dogs
• Cats
• Horses
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Orthopedics
• Trauma/Wound Care
• Other Applications
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Veterinary Clinics & Hospitals
• Veterinary Research Institutes
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Animal
  • 1.2.3. Application
  • 1.2.4. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information/Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Model 1: Commodity Flow Analysis
  • 1.7.2. Model 2: Bottom-Up Analysis
  • 1.7.3. Model 3 Multivariate Analysis
• 1.8. List of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary/Related Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Technological Breakthroughs in Stem Cell Engineering and Translational Research
    • 3.2.1.2. Rising Commercial Adoption and Veterinary Demand for Advanced Therapies
    • 3.2.1.3. Growing Awareness and Demand for Regenerative Medicine in Companion Animals
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Cost and Limited Reimbursement for Advanced Therapies
    • 3.2.2.2. Regulatory Challenges and Safety Concerns in Veterinary Applications
  • 3.2.3. Market Opportunity Analysis
• 3.3. Pricing Model Analysis
• 3.4. Disease Prevalence Analysis
• 3.5. Technology Landscape
• 3.6. Estimated Animal Population by Key Species & Key Countries, 2025
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Forces Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Companion Animal Regenerative Medicine Market: Product Estimates & Trend Analysis

• 4.1. Companion Animal Regenerative Medicine Market, By Product: Segment Dashboard
• 4.2. Companion Animal Regenerative Medicine Market, By Product Movement Analysis
• 4.3. Companion Animal Regenerative Medicine Market Estimates & Forecasts, by Product, 2021 to 2033 (USD Million)
• 4.4. Stem Cells
  • 4.4.1. Stem Cells Market Estimates and Forecasts, 2021 - 2033(USD Million)
• 4.5. Platelet-Rich Plasma (PRP)
  • 4.5.1. Platelet-Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033(USD Million)
• 4.6. Other Products
  • 4.6.1. Other Products Market Estimates and Forecasts, 2021 - 2033(USD Million)

Chapter 5. Companion Animal Regenerative Medicine Market: By Animal Estimates & Trend Analysis

• 5.1. Companion Animal Regenerative Medicine Market, By Animal: Segment Dashboard
• 5.2. Companion Animal Regenerative Medicine Market, By Animal Movement Analysis
• 5.3. Companion Animal Regenerative Medicine Market Estimates & Forecasts, by Animal, 2021 to 2033 (USD Million)
• 5.4. Dogs
  • 5.4.1. Dogs Market Estimates and Forecasts, 2021 - 2033(USD Million)
• 5.5. Cats
  • 5.5.1. Cats Market Estimates and Forecasts, 2021 - 2033(USD Million)
• 5.6. Horses
  • 5.6.1. Horses Market Estimates and Forecasts, 2021 - 2033(USD Million)
• 5.7. Others
  • 5.7.1. Others Market Estimates and Forecasts, 2021 - 2033(USD Million)

Chapter 6. Companion Animal Regenerative Medicine Market: By Application Estimates & Trend Analysis

• 6.1. Companion Animal Regenerative Medicine Market, By Application: Segment Dashboard
• 6.2. Companion Animal Regenerative Medicine Market, By Application Movement Analysis
• 6.3. Companion Animal Regenerative Medicine Market Estimates & Forecasts, by Application, 2021 to 2033 (USD Million)
• 6.4. Orthopedics
  • 6.4.1. Orthopedics Market Estimates and Forecasts, 2021 - 2033(USD Million)
• 6.5. Trauma/Wound Care
  • 6.5.1. Trauma/Wound Care Market Estimates and Forecasts, 2021 - 2033(USD Million)
• 6.6. Other Applications
  • 6.6.1. Other Applications Market Estimates and Forecasts, 2021 - 2033(USD Million)

Chapter 7. Companion Animal Regenerative Medicine Market: By End Use Estimates & Trend Analysis

• 7.1. Companion Animal Regenerative Medicine Market, By End Use: Segment Dashboard
• 7.2. Companion Animal Regenerative Medicine Market, By End Use Movement Analysis
• 7.3. Companion Animal Regenerative Medicine Market Estimates & Forecasts, by End Use, 2021 to 2033 (USD Million)
• 7.4. Veterinary Clinics & Hospitals
  • 7.4.1. Veterinary Clinics & Hospitals Market Estimates and Forecasts, 2021 - 2033(USD Million)
• 7.5. Veterinary Research Institutes
  • 7.5.1. Veterinary Research Institutes Market Estimates and Forecasts, 2021 - 2033(USD Million)

Chapter 8. Companion Animal Regenerative Medicine Market: By Regional Estimates & Trend Analysis

• 8.1. Region Market Dashboard
• 8.2. Region Market Share Analysis, 2025 & 2033
• 8.3. North America
  • 8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. U.S
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Australia
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. South Korea
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. Saudi Arabia
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.6. Qatar
    • 8.7.6.1. Key Country Dynamics
    • 8.7.6.2. Competitive Scenario
    • 8.7.6.3. Regulatory Framework
    • 8.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.7. Oman
    • 8.7.7.1. Key Country Dynamics
    • 8.7.7.2. Competitive Scenario
    • 8.7.7.3. Regulatory Framework
    • 8.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
• 9.3. Company Profiles
  • 9.3.1. Boehringer Ingelheim International GmbH
    • 9.3.1.1. Participant's Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Product/Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Zoetis Services LLC
    • 9.3.2.1. Participant's Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Product/Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Dechra
    • 9.3.3.1. Participant's Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Product/Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Integra Lifesciences
    • 9.3.4.1. Participant's Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Product/Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Vetherapy
    • 9.3.5.1. Participant's Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Product/Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Vetstem, Inc.
    • 9.3.6.1. Participant's Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Product/Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Ardent
    • 9.3.7.1. Participant's Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Product/Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Enso Discoveries
    • 9.3.8.1. Participant's Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Product/Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Animal Cell Therapies, Inc.
    • 9.3.9.1. Participant's Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Product/Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Vetbiologics
    • 9.3.10.1. Participant's Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Product/Service Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. Medrego
    • 9.3.11.1. Participant's Overview
    • 9.3.11.2. Financial Performance
    • 9.3.11.3. Product/Service Benchmarking
    • 9.3.11.4. Strategic Initiatives
  • 9.3.12. Vivos Inc (IsoPet)
    • 9.3.12.1. Participant's Overview
    • 9.3.12.2. Financial Performance
    • 9.3.12.3. Product/Service Benchmarking
    • 9.3.12.4. Strategic Initiatives